Mitsubishi UFJ Asset Management Co. Ltd. Purchases 1,995,491 Shares of Zoetis Inc. $ZTS

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Zoetis Inc. (NYSE:ZTS) by 113.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,761,920 shares of the company’s stock after buying an additional 1,995,491 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.84% of Zoetis worth $586,671,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Nova Wealth Management Inc. purchased a new position in Zoetis during the 1st quarter valued at about $25,000. 1248 Management LLC bought a new stake in shares of Zoetis in the 1st quarter worth approximately $27,000. Saudi Central Bank bought a new stake in shares of Zoetis in the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC raised its holdings in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC raised its holdings in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday. Argus restated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. UBS Group cut their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Stifel Nicolaus set a $140.00 target price on Zoetis in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Zoetis presently has an average rating of “Moderate Buy” and a consensus price target of $191.00.

Zoetis Stock Up 0.5%

ZTS stock opened at $120.20 on Friday. Zoetis Inc. has a twelve month low of $117.26 and a twelve month high of $181.85. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm has a market cap of $53.27 billion, a PE ratio of 20.69, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The business has a 50 day moving average of $144.21 and a 200 day moving average of $152.60.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the previous year, the company posted $1.58 earnings per share. The company’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.